The $80M upfront and $20M near-term milestone provide significant non-dilutive capital to fund BHV-1300's Phase 3 program and broader pipeline. The ~20% royalty on Ono's sales in Japan, Korea, Taiwan, and ASEAN adds long-term revenue potential. Watch for the stability test results and Ono's continuation decision within the next year, which triggers the $20M milestone and confirms Ono's commitment.
Price Chart
Executive Summary
Biohaven entered a strategic licensing agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio (BHV-1300, BHV-1310, BHV-1320) in Japan, South Korea, Taiwan, and ASEAN. Biohaven receives an $80 million upfront payment, a potential $20 million milestone within a year, and ~20% royalties on net sales in the licensed territory, while retaining all rights outside the region. This non-dilutive capital validates Biohaven's platform and funds ongoing Phase 3 development of BHV-1300 in Graves' disease.
Key Financial Metrics
Key Facts
- Biohaven granted Ono an exclusive license to develop/commercialize BHV-1300, BHV-1310, and BHV-1320 in Japan, South Korea, Taiwan, and ASEAN.
- Biohaven receives $80 million upfront, non-creditable and non-refundable.
- Biohaven eligible for a $20 million milestone payment upon Ono's receipt of stability test results and decision to continue development, anticipated within a year.
- Ono will pay royalties of approximately 20% on net sales in the licensed territory.
- Biohaven retains all rights outside the licensed territory, including the US, Europe, and China.
- BHV-1300 is in Phase 3 development for Graves' disease; Phase 1b data showed deep reduction in pathogenic autoantibodies and rapid normalization of thyroid hormones.
- The agreement is subject to an Upstream License Agreement with Yale University (dated January 1, 2021).
- Ono is responsible for development, regulatory, and commercialization costs in the territory.
- Biohaven will continue to conduct ongoing studies (BHV1300-302 and BHV1300-203) with Ono funding territory-specific costs.
- The agreement includes a non-compete clause for pan IgG1/2/4 degraders and a right of first negotiation for certain follow-on compounds.
Financial Impact
Biohaven receives $80M upfront plus up to $20M milestone within ~1 year, totaling $100M in near-term non-dilutive payments. Royalties of ~20% on Ono's net sales in the licensed territory provide ongoing revenue. Biohaven retains full value of the portfolio outside the licensed region.
Risk Factors
- The $20M milestone is contingent on Ono's receipt of stability test results and its decision to continue development; if Ono declines, the agreement terminates and the milestone is not paid.
- Clinical and regulatory risks for BHV-1300 in Phase 3 Graves' disease and other indications.
- Royalty rates are subject to reductions for generic competition, loss of patent coverage, and third-party license payments.
- Ono's commercialization efforts in ASEAN countries require mutual agreement, which may delay or limit market access.
- The agreement is subject to Yale's retained rights under the Upstream License Agreement.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000080 |
| Exhibit: exhibit991-onopressrelease.htm | 0001935979-26-000080 |
| Document: bhvn-20261008.htm | 0001935979-26-000080 |
| Document: 0001935979-26-000080-index-headers.html | 0001935979-26-000080 |
| Document: 0001935979-26-000080-index.html | 0001935979-26-000080 |
| Document: 0001935979-26-000080.txt | 0001935979-26-000080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $14.69 | awaiting T+5 | — | $14.95 (+1.80%) |
Oct 15, 2026 11d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $14.95 (+38.73%) |
Sep 9, 2026 6w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $14.95 (−16.93%) |
Aug 26, 2026 8w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $14.95 (−11.77%) |
Aug 10, 2026 11w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $14.95 (+3.21%) |
Jul 9, 2026 15w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $14.95 (−3.83%) |
May 27, 2026 21w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $14.95 (+46.04%) |
May 4, 2026 25w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $14.95 (−54.02%) |
May 4, 2026 25w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $14.95 (+54.02%) |
May 4, 2026 25w ago | 8-K | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $14.95 (+54.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers